within Pharmacolibrary.Drugs.ATC.A;

model A05AA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.245,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.618,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Obeticholic acid is a semi-synthetic bile acid analog that acts as a potent agonist of the farnesoid X receptor (FXR). It is used for the treatment of primary biliary cholangitis (PBC) in adults, particularly in those who show inadequate response to or are intolerant of ursodeoxycholic acid. It is an FDA-approved drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers, both male and female, after single and repeated oral administration.</p><h4>References</h4><ol><li><p>Valluri, VR, et al., &amp; Polagani, SR (2021). A novel LC-MS/MS method for simultaneous estimation of obeticholic acid, glyco-obeticholic acid, tauro-obeticholic acid in human plasma and its application to a pharmacokinetic study. <i>Journal of separation science</i> 44(7) 1307–1323. DOI:<a href=&quot;https://doi.org/10.1002/jssc.202001050&quot;>10.1002/jssc.202001050</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33395497/&quot;>https://pubmed.ncbi.nlm.nih.gov/33395497</a></p></li><li><p>Hu, C, et al., &amp; Ding, L (2022). A Sensitive HPLC-MS/MS Method for Determination of Obeticholic Acid in Human Plasma: Application to a Pharmacokinetic Study in Healthy Volunteers. <i>Journal of chromatographic science</i> 60(6) 545–550. DOI:<a href=&quot;https://doi.org/10.1093/chromsci/bmab098&quot;>10.1093/chromsci/bmab098</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34313291/&quot;>https://pubmed.ncbi.nlm.nih.gov/34313291</a></p></li><li><p>Friedman, ES, et al., &amp; Wu, GD (2018). FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. <i>Gastroenterology</i> 155(6) 1741–1752.e5. DOI:<a href=&quot;https://doi.org/10.1053/j.gastro.2018.08.022&quot;>10.1053/j.gastro.2018.08.022</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30144429/&quot;>https://pubmed.ncbi.nlm.nih.gov/30144429</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A05AA04;
